MBIO Logo

Mustang Bio, Inc. (MBIO) 

NASDAQ
Market Cap
$9.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
609 of 775
Rank in Industry
329 of 433

Largest Insider Buys in Sector

MBIO Stock Price History Chart

MBIO Stock Performance

About Mustang Bio, Inc.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare …

Insider Activity of Mustang Bio, Inc.

Over the last 12 months, insiders at Mustang Bio, Inc. have bought $0 and sold $0 worth of Mustang Bio, Inc. stock.

On average, over the past 5 years, insiders at Mustang Bio, Inc. have bought $838,232 and sold $40,682 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $2,582 was made by Litchman Manuel MD (director) on 2022‑09‑13.

List of Insider Buy and Sell Transactions, Mustang Bio, Inc.

2022-09-13Purchasedirector
5,000
0.0041%
$0.52$2,582-30.59%
2022-09-13Purchasedirector
5,000
0.0041%
$0.52$2,582-30.59%
2022-03-18Purchasedirector
5,000
0.0041%
$0.74$3,695-34.09%
2022-03-18Purchasedirector
4,094
0.0034%
$0.74$3,025-34.09%
2021-12-14SaleSVP, Fin. & Corp. Controller
4,374
0.0003%
$1.83$8,004-62.80%
2021-10-27PurchasePresident and CEO
65,000
0.0048%
$2.24$145,600-65.88%
2021-10-12SaleSVP, Fin. & Corp. Controller
4,450
0.0003%
$2.28$10,146-64.93%
2021-07-30PurchasePresident and CEO
86,206
0.0063%
$2.91$250,859-59.52%
2021-04-09SaleSVP, Fin. & Corp. Controller
2,423
0.0002%
$3.36$8,141-22.88%
2021-03-05PurchasePresident and CEO
165,562
0.0135%
$3.12$516,553-12.46%
2020-12-15PurchasePresident and CEO
100,000
0.0114%
$2.91$291,000+2.69%
2020-12-14Purchasedirector
100,000
0.0115%
$2.66$266,000+12.96%
2020-12-08SaleSVP, Fin. & Corp. Controller
5,185
0.0006%
$3.03$15,711-1.29%
2020-10-21SaleSVP, Fin. & Corp. Controller
3,056
0.0004%
$2.97$9,076+11.39%
2020-06-11PurchasePresident and CEO
153,846
0.0228%
$3.25$500,000+0.15%
2020-05-22SalePresident and CEO
12,373
0.0018%
$3.04$37,614+5.84%
2020-05-22SaleSVP, Fin. & Corp. Controller
880
0.0001%
$3.04$2,675+5.84%
2020-05-21PurchasePresident and CEO
90,000
0.0134%
$3.13$281,700+4.49%
2020-05-14PurchasePresident and CEO
90,000
0.0132%
$2.79$251,100+16.01%
2020-03-31SaleSVP, Fin. & Corp. Controller
3,033
0.0004%
$2.64$8,007+20.90%

Insider Historical Profitability

<0.0001%
Litchman Manuel MDdirector
1098987
2.3415%
$0.21141<0.0001%
ROSENWALD LINDSAY A MDdirector
299181
0.6374%
$0.2140<0.0001%
Achenbach BrianSVP, Fin. & Corp. Controller
144729
0.3084%
$0.2138<0.0001%
Herskowitz Neildirector
71000
0.1513%
$0.2110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$218,400.000.6210,000-51.81%-$234,794.56<0.01
The Vanguard Group$213,916.000.59205,688+14.55%+$27,171.10<0.0001
BlackRock$103,067.000.2899,103-1.34%-$1,399.84<0.0001
Geode Capital Management$50,345.000.1448,397-2.81%-$1,455.31<0.0001
Renaissance Technologies$37,000.000.135,390-10.83%-$4,495.62<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.